Company Profiles

driven by the PitchBook Platform

Diasome Pharmaceuticals

Description

Developer of novel and cell targeted therapies designed to treat diabetes and obesity. The company's cell targeted therapies includes research and development of a oral compound, cell receptor targeting, insulin replacement and hepatic (liver) glucose metabolism which are based on new insights of normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound for Type 2 diabetes population that enables its clients to have a significant impact in treating obesity and diabetes.

2004

Founded

PRIVATE

Status

Later Stage VC

Latest Deal Type

$4.35M

Latest Deal Amount

$17.6M

Total Amount Raised

2

Investors

Description

Developer of novel and cell targeted therapies designed to treat diabetes and obesity. The company's cell targeted therapies includes research and development of a oral compound, cell receptor targeting, insulin replacement and hepatic (liver) glucose metabolism which are based on new insights of normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound for Type 2 diabetes population that enables its clients to have a significant impact in treating obesity and diabetes.

Website:

www.diasomepharmaceuticals.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

10000 Cedar Avenue Suite 6 Cleveland, OH 44106United States +1 (216) 444-7110
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Diasome Pharmaceuticals's full profile, request a free trial.

Diasome Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Diasome Pharmaceuticals Investors (2)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Devon Park BioventuresVenture CapitalMinority000 0000000 0000
L2 PharmaMinority000 0000000 0000
Devon Park Bioventures Venture Capital
L2 Pharma

Diasome Pharmaceuticals Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Robert GehoChief Executive Officer, Co-Founder & Board Member
Helga KautskyChief Financial Officer & Board Member
Stephen Charles Ph.DChief Technology Officer
W. Geho Ph.DCo-Founder, Chief Scientific Officer & Board Member
John LauHead, Chemistry
Robert Geho Chief Executive Officer, Co-Founder & Board Member
Helga Kautsky Chief Financial Officer & Board Member
Stephen Charles Ph.D Chief Technology Officer
W. Geho Ph.D Co-Founder, Chief Scientific Officer & Board Member
John Lau Head, Chemistry

Diasome Pharmaceuticals Board Members (11)

NameRepresentingRoleSinceContact
Info
Alexander FlemingSelfBoard Member & Scientific Advisor000 0000
Arthur Rubenstein MDSelfBoard Member & Scientific Advisor000 0000
Devang Kantesaria MDDevon Park BioventuresGeneral Partner000 0000
Frank McCaneySelfBoard Member000 0000
Guiseppe ZoccoSelfBoard Member000 0000
Alexander Fleming Board Member & Scientific Advisor Self
Arthur Rubenstein MD Board Member & Scientific Advisor Self
Devang Kantesaria MD General Partner Devon Park Bioventures
Frank McCaney Board Member Self
Guiseppe Zocco Board Member Self
Request full access to PitchBook